US Stock MarketDetailed Quotes

BEAM Beam Therapeutics

Watchlist
  • 32.400
  • +3.790+13.25%
Close Feb 14 16:00 ET
  • 32.480
  • +0.080+0.25%
Post 19:59 ET
2.68BMarket Cap-20.51P/E (TTM)

About Beam Therapeutics Company

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Company Profile

SymbolBEAM
Company NameBeam Therapeutics
Listing DateFeb 6, 2020
Issue Price17.00
Founded2017
CEOMr. John Evans
MarketNASDAQ
Employees436
Fiscal Year Ends12-31
Address238 Main Street,9th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142-1016
Phone1-857-327-8775

Company Executives

  • Name
  • Position
  • Salary
  • John Evans
  • Chief Executive Officer, Principal Accounting Officer and Director
  • 6.28M
  • Dr. Amy Simon, M.D.
  • Chief Medical Officer
  • 2.55M
  • Sravan K. Emany
  • Chief Financial Officer
  • --
  • Dr. Christine Bellon, PhD
  • Chief Legal Officer and Secretary
  • 2.28M
  • Dr. Giuseppe Ciaramella, PhD
  • President
  • 2.79M
  • Chirfi Guindo
  • Director
  • --
  • Dr. John M. Maraganore,PhD
  • Independent Director
  • 435.22K
  • Dr. Carole Ho, M.D.
  • Independent Director
  • 442.72K
  • Graham K. Cooper
  • Independent Director
  • 450.22K
  • Dr. Mark C. Fishman, M.D.
  • Lead Independent Director
  • 465.22K
  • Christi Shaw
  • Independent Director
  • 772.68K
  • Kathleen E. Walsh
  • Independent Director
  • 447.72K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More